Vedolizumab: all 88 studies that test it

Page 1 of 1. Open to participants first (20), then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative ColitisRecruitingNCT06850727Phase 2
• Early Vedolizumab as First-Line for Immune-Related Colitis Therapy TrialRecruitingNCT06841705Phase 2
• Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity ConditioningRecruitingNCT06815003Phase 2
• Subcutaneous Interval Lengthening of Vedolizumab for Economic ResearchRecruitingNCT06584162Phase 4
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community SettingRecruitingNCT06581328Phase 4
• A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic PouchitisRecruitingNCT06443502Phase 3
• A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)RecruitingNCT06405087Phase 3
• Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With CancerRecruitingNCT06337695Phase 2/3
• VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's DiseaseRecruitingNCT06257706Phase 4
• Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.RecruitingNCT06180382Phase 4
• A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's DiseaseRecruitingNCT06100289Phase 3
• A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)RecruitingNCT06095128Phase 4
• Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal InvolvementRecruitingNCT06066840Phase 4
• A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's DiseaseRecruitingNCT05837897Phase 3
• Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative ColitisRecruitingNCT05481619Phase 4
• A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)RecruitingNCT05442567Phase 3
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)RecruitingNCT04779320Phase 3
• Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With CancerRecruitingNCT03819296Phase 1
• Autologous Stem Cell Transplant for Crohn's DiseaseRecruitingNCT03219359Phase 2
• Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV InfectionRecruitingNCT03147859Phase 2
• A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's DiseaseCompletedNCT04804540Phase 4Results posted
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)CompletedNCT04779307Phase 3Results posted
• A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's DiseaseActive, not recruitingNCT04738942Phase 3Results posted
• A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy ParticipantsCompletedNCT03961308Phase 1Results posted
• A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy ParticipantsCompletedNCT03961295Phase 1Results posted
• A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy ParticipantsCompletedNCT03949621Phase 1Results posted
• A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy ParticipantsCompletedNCT03948581Phase 1Results posted
• Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) TransplantationCompletedNCT03657160Phase 3Results posted
• A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese ParticipantsCompletedNCT03329209Phase 1Results posted
• Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.CompletedNCT03234907Phase 3Results posted
• Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)CompletedNCT03196427Phase 2Results posted
• Defining Predictors of RT Response to Vedolizumab in IBDCompletedNCT03142321Phase 4Results posted
• Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)CompletedNCT03138655Phase 2Results posted
• Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative ColitisCompletedNCT03029143Phase 4Results posted
• A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)TerminatedNCT02993783Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic PouchitisCompletedNCT02790138Phase 4Results posted
• Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment InterruptionCompletedNCT02788175Phase 1Results posted
• Triple Combination Therapy in High Risk Crohn's Disease (CD)CompletedNCT02764762Phase 4Results posted
• Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's DiseaseTerminatedNCT02743806Phase 4Results posted
• Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCTCompletedNCT02728895Phase 1Results posted
• Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced MelanomaTerminatedNCT02723006Phase 1Results posted
• Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's DiseaseCompletedNCT02630966Phase 4Results posted
• A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's DiseaseCompletedNCT02620046Phase 3Results posted
• Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative ColitisCompletedNCT02611830Phase 3Results posted
• Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)CompletedNCT02611817Phase 3Results posted
• Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's DiseaseCompletedNCT02559713Phase 4Results posted
• An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative ColitisCompletedNCT02497469Phase 3Results posted
• Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's DiseaseCompletedNCT02425111Phase 3Results posted
• Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous AdministrationCompletedNCT02163421Phase 1Results posted
• Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative ColitisCompletedNCT02039505Phase 3Results posted
• Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's DiseaseCompletedNCT02038920Phase 3Results posted
• Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of VedolizumabCompletedNCT01981616Phase 1Results posted
• Study of Vedolizumab in Patients With Moderate to Severe Crohn's DiseaseCompletedNCT01224171Phase 3Results posted
• Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative ColitisCompletedNCT01177228Phase 2Results posted
• An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's DiseaseCompletedNCT00790933Phase 3Results posted
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative ColitisCompletedNCT00783718Phase 3Results posted
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's DiseaseCompletedNCT00783692Phase 3Results posted
• Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's DiseaseCompletedNCT00619489Phase 2Results posted
• The Association Between Interleukin-7 Receptor Gene Polymorphism and the Risk of Ulcerative ColitisCompletedNCT07398586Phase 4
• A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to VedolizumabActive, not recruitingNCT06880744Phase 3
• Association Between Effectiveness of Mirikizumab and UC Patients With High Neutrophilic Infiltration in Epithelium of the Colonic MucosaCompletedNCT06626165Phase 4
• Vedolizumab for the Treatment of Collagenous GastritisActive, not recruitingNCT06317220Phase 2
• Efficacy and Safety of Vedolizumab in Biologic-naïve Korean Patients With Moderate to Severe Inflammatory Bowel DiseaseStatus unknownNCT04919252Phase 3
• Vedolizumab for Immune Mediated ColitisStatus unknownNCT04797325Phase 2
• Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or MelanomaActive, not recruitingNCT04407247Phase 1/2
• Determination of the Optimal Treatment Target in Ulcerative ColitisCompletedNCT04259138Phase 4
• A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)CompletedNCT04120415Phase 2
• Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative ColitisStatus unknownNCT04006080Phase 4
• EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative ColitisCompletedNCT03679546Phase 4
• Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin LesionsCompletedNCT03629379Phase 4
• Vedolizumab Treatment in HIV-Infected Subjects Without Previous Antiretroviral TherapyStatus unknownNCT03577782Phase 1/2
• Evaluating the Combined Effect of Vedolizumab and Semi-Vegetarian Diet on Ulcerative Colitis.WithdrawnNCT03309865Early Phase 1
• An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative ColitisWithdrawnNCT03237260Phase 4
• Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative ColitisActive, not recruitingNCT03221036Phase 3
• Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel DiseaseWithdrawnNCT03035058Phase 3
• An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic InfectionTerminatedNCT02972450Phase 1/2
• Vedolizumab Induction May Prevent Celiac EnteritisTerminatedNCT02929316Phase 2
• Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's DiseaseWithdrawnNCT02913508Phase 2
• Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)TerminatedNCT02878083Not applicable
• Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel DiseasesCompletedNCT02862132Not applicable
• Vedolizumab Post Op StudyWithdrawnNCT02834754Phase 2
• Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNFWithdrawnNCT02820493Phase 4
• Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's DiseaseTerminatedNCT02768532Phase 4
• Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction StudyWithdrawnNCT02760615Phase 4
• Clinical and Molecular Phenotyping in IBDCompletedNCT02694588Not applicable
• A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD StudyCompletedNCT02646683Phase 4
• An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative ColitisCompletedNCT02646657Phase 4
• Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's PatientsCompletedNCT00655135Phase 2

← Vedolizumab overview